Welcome to our dedicated page for HCW Biologics SEC filings (Ticker: HCWB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCW Biologics Inc. filings document a clinical-stage biopharmaceutical issuer developing fusion immunotherapeutics through the TOBI and TRBC platforms. Its SEC records include 8-K reports for operating results, clinical and regulatory program updates, material agreements, licensing activity and Nasdaq-related corporate events, along with registration statements covering securities offerings and related capital-structure disclosures.
HCWB proxy and governance filings describe annual meeting matters, shareholder voting procedures and bylaw amendments, including quorum provisions. The company’s formal disclosures also address product-candidate development, financial condition, emerging growth company status, risk factors, ownership and governance controls relevant to its public-company reporting profile.
HCW Biologics Inc. agreed to sell 903,614 units in a private placement at $1.6599 per unit, for approximately $1.5 million in gross proceeds before offering expenses. Each unit includes one pre-funded warrant to purchase one common share and a right to receive one common stock purchase warrant to purchase one share, subject to stockholder approval. The pre-funded warrants are immediately exercisable at $0.0001 per share and remain exercisable until exercised in full; exercise is limited so the holder’s beneficial ownership does not exceed 9.99% of common stock outstanding immediately after exercise.
If stockholders approve, HCW Biologics will issue common warrants exercisable for up to 903,614 shares at $1.66 per share. They will expire five and one-half years after issuance and carry a 4.99% beneficial ownership limit, subject to adjustment by the holder. HCW Biologics intends to use net proceeds for working capital and general corporate purposes, including clinical development activities. It also agreed to file a Form S-1 resale registration statement within 15 trading days following closing and use commercially reasonable efforts to have it declared effective within 60 days following closing.
HCW Biologics Inc. (HCWB) reported that on September 9, 2026 it filed Amendment No. 1 to its Preliminary Proxy Statement for an upcoming Special Meeting of Stockholders. After considering stockholder feedback, the board decided not to seek approval of Proposal No. 2 from the original preliminary proxy, which would have asked stockholders to approve an amended performance-based equity plan for eligible officers, directors and employees, and removed that proposal in the amendment. The amendment also changes the date of the Special Meeting, the record date for stockholders entitled to vote, and certain related dates, while making no other substantive changes to the original preliminary proxy.
HCW Biologics Inc. (HCWB) has amended its preliminary proxy statement and set a virtual special meeting for November 17, 2026 to seek stockholder approval of a single substantive item. Proposal One asks stockholders to approve, for purposes of Nasdaq Listing Rule 5635(d), the issuance of Common Warrants exercisable for up to 618,682 shares of common stock, issued in connection with a $1.6 million private placement completed on July 29, 2026, at an exercise price of $2.585 per share.
Nasdaq’s “20% Rule” currently caps issuance upon warrant exercise to 319,370 shares, approximately 19.99% of shares outstanding immediately before the Securities Purchase Agreement. Approval would permit issuance above this Exchange Cap, enabling full exercise of the Common Warrants but diluting existing holders’ voting and economic interests if exercised. If Proposal One is not approved, the Common Warrants remain outstanding but cannot be exercised above the Exchange Cap, which the company states may limit anticipated financing benefits from the offering.
The amendment also removes a prior proposal to approve an amended performance-based equity plan and updates the special meeting and record dates.
HCW Biologics Inc. (HCWB) entered into an Exclusive Distribution Agreement with Akron Biotech to commercialize its commercial-ready molecule HCW11-006 as a reagent for cell therapy manufacturing and other ex vivo applications worldwide, excluding China. The agreement has a five-year term from closing, which is subject to satisfactory due diligence and product testing and is expected to close no later than November 30, 2026.
HCW Biologics and Akron plan to enter a Supply Agreement within 60 days after closing. Assuming closing occurs, HCW Biologics will receive $200,000 at closing, $100,000 within 30 days of executing the Supply Agreement, and $100,000 on each of the first and second anniversaries of closing, plus additional quarterly payments for technical support as needed. HCW Biologics also committed to continue supplying HCW11-006 to support existing Akron customers if it terminates the agreement for convenience.
HCW Biologics Inc. (HCWB) has called an October 27, 2026 virtual special stockholder meeting to vote on two main items. First, stockholders are asked to approve, for Nasdaq Listing Rule 5635(d) purposes, the issuance of Common Warrants exercisable for up to 618,682 shares of common stock at $2.585 per share, issued in a $1.6 million private placement completed on July 29, 2026. Approval would allow potential issuance above the 19.99% “Exchange Cap” tied to that financing.
Second, HCW Biologics seeks approval of an Amended and Restated 2021 Equity Incentive Plan, adding a 2,500,000‑share Special Reserve for performance-based awards under the 2026 Special Reserve Plan and eliminating the plan’s automatic annual “evergreen” increase. As of September 1, 2026, 2,236,324 shares of common stock were outstanding and only 15,704 shares remained available under the existing plan. Special Reserve awards would be granted in 20% tranches only when the stock price reaches escalating milestones beginning at $5 per share, with vesting over one to two years, to support retention and align compensation with stockholder value. The board recommends voting FOR both proposals.
HCW Biologics Inc. (HCWB) filed Amendment No. 1 to its Registration Statement on Form S-1 (Registration No. 333-298452). The company states this is an exhibits-only filing, meaning the substantive terms of the underlying registration statement remain unchanged and only the exhibit list and related materials are being updated. The amendment adds or updates various corporate, financing, warrant, equity plan, licensing and debt-related agreements as exhibits, along with legal opinions and Inline XBRL files, while expressly leaving the rest of the registration statement as previously filed.
HCW Biologics Inc. (HCWB), a clinical-stage immunotherapy company, has filed a Form S-1 to register the resale of up to 1,237,364 shares of common stock by selling stockholders. These include 218,682 shares issued in a July 29, 2026 PIPE financing, up to 400,000 shares issuable upon exercise of pre-funded warrants at $0.0001 per share, and up to 618,682 shares issuable upon exercise of common warrants at $2.585 per share, subject to stockholder approval.
The July 2026 PIPE generated approximately $1.6 million in gross proceeds for HCWB, with participation by its CEO, board chair and an executive. HCWB will not receive proceeds from resale of registered shares but may receive up to about $1.6 million if the common warrants are approved and exercised for cash, to be used for general corporate purposes.
As of August 20, 2026, HCWB had 1,836,324 shares outstanding, and its stock closed at $2.52 on August 17, 2026, after a 1-for-6 reverse split effective June 30, 2026. The filing highlights significant risks, including potential dilution from warrant exercises, substantial resale overhang, past Nasdaq listing compliance issues, material weaknesses in internal controls, restated EPS for the quarter ended March 31, 2026, and the speculative nature of investing in an early-stage biopharmaceutical issuer.
HCW Biologics Inc. reported interim results for the three and six months ended June 30, 2026. Total assets were $26.8 million, up from $24.5 million at December 31, 2025, driven mainly by an increase in investments to $4.9 million and stable property, plant and equipment of about $20.7 million. Cash and cash equivalents declined to $741,324, while total current liabilities were $18.6 million, leaving a tight liquidity position.
For the six months, revenue rose to $6.7 million from $11,615 a year earlier, primarily from a March 2026 license agreement with Beijing Trimmune Biotech that generated $6.3 million of license revenue and $351,730 of services revenue. This shifted operating results to a small operating income of $69,420 versus a prior-period operating loss of $5.4 million. However, after equity dividends to an investor, the net loss attributable to common stockholders was $13.4 million, and net cash used in operating activities was $5.5 million.
Management states that recurring losses, negative operating cash flows, limited cash, and lack of product revenue raise substantial doubt about the company’s ability to continue as a going concern for at least 12 months, and this doubt was not alleviated. HCW completed multiple equity financings and warrant transactions in 2025–2026, executed two reverse stock splits, and maintains a $20 million standby equity purchase agreement to access additional capital if conditions allow.
HCW Biologics Inc. reported second-quarter and first-half 2026 results alongside business and clinical updates. Preliminary human data from a Phase 1 alopecia areata study of lead autoimmune candidate HCW9302 showed early signs of efficacy with ≥25% SALT score reductions in all three patients in the second dose cohort, without dose-limiting toxicities or key IL‑2–related side effects.
The company re-acquired ex vivo rights to two commercial-ready molecules from AlloTera Therapeutics and is seeking a partner to commercialize HCW9206 and related molecules as reagents for CAR‑T manufacturing. It is advancing tetravalent T‑cell engager HCW11-018b, having requested a Type B pre‑IND meeting with the FDA, targeting a first clinical trial in the first half of 2027, subject to authorization.
HCW completed $5.6 million of equity financings in May and July 2026 involving common stock, pre-funded warrants and common warrants. Revenue rose to $135,568 for the quarter and $6.7 million for the first half of 2026, driven by a licensing agreement with Trimmune. Net loss was $5.2 million for the quarter and $1.7 million for the first half, with a fair value loss on warrant liabilities partly offset by a gain on extinguishment of a liability. As of June 30, 2026, the company reported substantial doubt about its ability to continue as a going concern without additional funding. Cash and cash equivalents were $741,324, and a one-for-six reverse stock split was effected on June 30, 2026. HCW regained compliance with Nasdaq bid price and equity listing rules, with a potential one-year discretionary panel monitor if conditions are maintained through September 22, 2026.